# Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

> **NCT05469893** · PHASE2 · RECRUITING · sponsor: **Irene Ghobrial, MD** · enrollment: 52 (estimated)

## Conditions studied

- High-risk Smoldering Multiple Myeloma
- Smoldering Multiple Myeloma
- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05469893
- **Lead sponsor:** Irene Ghobrial, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-10
- **Primary completion:** 2030-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469893, "Immuno-PRISM (PRecision Intervention Smoldering Myeloma)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05469893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*